Nakajima Shinichiro, Caravaggio Fernando, Mamo David C, Mulsant Benoit H, Chung Jun Ku, Plitman Eric, Iwata Yusuke, Gerretsen Philip, Uchida Hiroyuki, Suzuki Takefumi, Mar Wanna, Wilson Alan A, Houle Sylvain, Graff-Guerrero Ariel
Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada.
Schizophr Res. 2015 May;164(1-3):263-7. doi: 10.1016/j.schres.2015.02.020. Epub 2015 Mar 8.
No study has examined dopamine D₂/₃ receptor (D₂/₃R) availability in antipsychotic-free older patients with schizophrenia.
We included patients with schizophrenia 50 years or older who were antipsychotic-free for at least 3 months. We compared non-displaceable binding potential (BPND) of [(11)C]-raclopride in the caudate, putamen, ventral striatum, and globus pallidus between patients and age- and sex-matched healthy controls.
Ten patients participated (antipsychotic-naive=4). No differences in BPND were found between patients and controls in any ROIs (F(1, 72)=.42, p=.52).
The preliminary results suggest no differences in D₂/₃R availability between antipsychotic-free older patients with schizophrenia and controls.
尚无研究考察未服用抗精神病药物的老年精神分裂症患者的多巴胺D₂/₃受体（D₂/₃R）可用性。
我们纳入了年龄在50岁及以上、至少3个月未服用抗精神病药物的精神分裂症患者。我们比较了患者与年龄和性别匹配的健康对照者在尾状核、壳核、腹侧纹状体和苍白球中[(11)C] - 雷氯必利的非置换性结合潜能（BPND）。
10名患者参与研究（初发未服抗精神病药物者 = 4名）。在任何感兴趣区域（ROI）中，患者与对照者之间的BPND均未发现差异（F(1, 72)=.42，p =.52）。
初步结果表明，未服用抗精神病药物的老年精神分裂症患者与对照者之间的D₂/₃R可用性无差异。
